Koek W, Patoiseau J F, Assié M B, Cosi C, Kleven M S, Dupont-Passelaigue E, Carilla-Durand E, Palmier C, Valentin J P, John G, Pauwels P J, Tarayre J P, Colpaert F C
Centre de Recherche Pierre Fabre, Castres Cedex, France.
J Pharmacol Exp Ther. 1998 Oct;287(1):266-83.
F 11440 (4-methyl-2-[4-(4-(pyrimidin-2-yl)-piperazino)-butyl]-2H, 4H-1,2,4-triazin-3,5-dione) was the outcome of a research effort guided by the hypothesis that the magnitude of the intrinsic activity of agonists at 5-HT1A receptors determines the magnitude of their antidepressant and anxiolytic-like effects. The affinity of F 11440 for 5-HT1A binding sites (pKi, 8.33) was higher than that of buspirone (pKi, 7.50), and somewhat lower than that of flesinoxan (pKi, 8.91). In vivo, F 11440 was 4- to 20-fold more potent than flesinoxan, and 30- to 60-fold more potent than buspirone, in exerting 5-HT1A agonist activity at pre- and postsynaptic receptors in rats (measured by, for example, its ability to decrease hippocampal extracellular serotonin (5-HT) levels and to increase plasma corticosterone levels, respectively). F 11440 did not have detectable antidopaminergic activity (unlike buspirone, which inhibited all of the directly observable behavioral effects of methylphenidate in rats), showed no evidence of antihistaminergic activity (unlike flesinoxan, which protected against the effects of a histamine aerosol in guinea pigs), and had a 70-fold separation between its 5-HT1A agonist and alpha-1 adrenergic antagonist properties (measured as the ability to inhibit the methoxamineinduced increase in blood pressure in rats), unlike flesinoxan, which showed a <3-fold separation. In HeLa cells expressing human 5-HT1A receptors, F 11440 decreased the forskolin-induced increase in AMP, and, based on its maximal effect, was found to have an intrinsic activity of 1.0 relative to that of 5-HT, which was significantly higher than that of buspirone (0.49), ipsapirone (0.46) and flesinoxan (0.93). Consistent with the aforementioned hypothesis, F 11440 produced anxiolytic- and antidepressant-like effects in animal models (i.e., increased punished responding in a pigeon conflict procedure and decreased immobility in a rat forced swimming test, respectively) that were more substantial than those of buspirone, ipsapirone and flesinoxan. Thus, F 11440, shown here to be a potent, selective, high efficacy 5-HT1A receptor agonist, appears to have the potential to exert marked anxiolytic and antidepressant activity in humans.
F 11440(4-甲基-2-[4-(4-(嘧啶-2-基)-哌嗪基)-丁基]-2H,4H-1,2,4-三嗪-3,5-二酮)是一项研究工作的成果,该研究基于这样的假设:5-HT1A受体激动剂的内在活性大小决定了它们抗抑郁和抗焦虑样效应的大小。F 11440对5-HT1A结合位点的亲和力(pKi,8.33)高于丁螺环酮(pKi,7.50),略低于氟司必林(pKi,8.91)。在体内,F 11440在大鼠的突触前和突触后受体上发挥5-HT1A激动剂活性时,其效力比氟司必林高4至20倍,比丁螺环酮高30至60倍(例如,分别通过其降低海马细胞外5-羟色胺(5-HT)水平和增加血浆皮质酮水平的能力来衡量)。F 11440没有可检测到的抗多巴胺能活性(与丁螺环酮不同,丁螺环酮可抑制大鼠中哌甲酯所有可直接观察到的行为效应),没有抗组胺能活性的证据(与氟司必林不同,氟司必林可保护豚鼠免受组胺气雾剂的影响),并且其5-HT1A激动剂和α-1肾上腺素能拮抗剂特性之间有70倍的差异(以抑制大鼠中甲氧明引起的血压升高的能力来衡量),而氟司必林的差异小于3倍。在表达人5-HT1A受体的HeLa细胞中,F 11440降低了福斯高林诱导的AMP增加,并且根据其最大效应,发现其相对于5-HT的内在活性为1.0,显著高于丁螺环酮(0.49)、伊沙匹隆(0.46)和氟司必林(0.93)。与上述假设一致,F 11440在动物模型中产生了抗焦虑和抗抑郁样效应(即分别增加了鸽子冲突程序中的惩罚反应和减少了大鼠强迫游泳试验中的不动时间),比丁螺环酮、伊沙匹隆和氟司必林的效应更显著。因此,F 11440在此处显示为一种强效、选择性、高效的5-HT1A受体激动剂,似乎有潜力在人类中发挥显著的抗焦虑和抗抑郁活性。